An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability of Simufilam 100 mg Tablets in Participants with Mild to Moderate Alzheimer’s Disease

Darby, David (Primary Chief Investigator (PCI))
Cao, Ting (Project Manager)
Kyndt, Chris (Partner Investigator (PI))
Brodtmann, Amy (Partner Investigator (PI))
Zeimer, Henry (Chief Investigator (CI))

Department of Neuroscience

Project: Research

Status	Finished
Effective start/end date	19/05/23 → 19/05/25

Keywords

Clinical trial
Alzheimer’s Disease
Simufilam

Clinical Trial Phase

Phase III (a & b)